For example, while olaparib has been FDA‐approved for metastatic CHEK2‐ and ATM‐mutated prostate cancer; therapeutic benefit in these patients was suboptimal in comparison to patients harboring BRCA1/2 mutations.30 This evidence concerns the gene BRCA1 and prostate carcinoma.